Similarly, knocking out of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) (targets of palbociclib or ibrancein in breast cancer), ERBB2 (target of trastuzumab in breast cancer), Bruton’s tyrosine kinase (BTK) (target of ibrutinib or imbruvica in hematopoietic cancer), CRBN (target of lenalidomide or revlimid in skin cancer), and CYP17A1 (target of abiraterone acetate or zytiga in prostate cancer) did not influence the fitness of cancer cell lines (Figure 2D). This evidence concerns the gene CDK6 and hematopoietic and lymphoid cell neoplasm.